JAZF1 and gastric cancer: More intriguingly, the survival analysis showed better OS in GC patients with higher miR-1275 expression and lower JAZF1 expression than in patients with lower miR-1275 expression (1- and 3-year OS: 55.7 and 33.5% vs. 34.0 and 17.0%, P = 0.0013) and higher JAZF1 expression (1- and 3-year OS: 72.3 and 36.6% vs. 17.7 and 17.7%, P < 0.001) (Fig. 4f).